Clinical trials: Lou Gehrig's Disease
Amyotrophic Lateral Sclerosis
Early Treatment of Amyotrophic Lateral Sclerosis (ALS) With Nutrition and Non-Invasive Positive Pressure Ventilation
The purposes of the study are to determine the energy balance and evaluate the nutritional status of patients with ALS, and to investigate the use of NIPPV as respiratory support to treat patients with ALS.
- Trial name
- NCT00116558
- Testing
- Early NIPPV, Standard NIPPV
- Where
- 12 sites in United States
- Volunteers
- 153 people
- Sponsor
- Edward Kasaraskis
Amyotrophic Lateral Sclerosis
Noninvasive Ventilation in ALS Patients With Mild Respiratory Involvement
Non-invasive ventilation or BiPAP®, which is a form of breathing support delivered through a facemask, is a successful treatment for the respiratory complications of amyotrophic lateral sclerosis (ALS).
- Trial name
- NCT00386464
- Testing
- noninvasive positive pressure ventilation
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Johns Hopkins University
Amyotrophic Lateral Sclerosis
Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS)
The purpose of this study is to compare the effectiveness of lithium combined with riluzole to riluzole combined with placebo in people with amyotrophic lateral sclerosis.
- Trial name
- NCT00818389
- Testing
- Lithium Carbonate, Riluzole
- Where
- 37 sites in United States, Canada
- Volunteers
- 84 people
- Sponsor
- Massachusetts General Hospital
Amyotrophic Lateral Sclerosis
Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients
The objective is to compare the efficacy and safety of masitinib in combination with riluzole versus matched placebo in combination with riluzole for the treatment of Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- NCT03127267
- Testing
- Masitinib (6.0), Riluzole, Masitinib (4.5)
- Where
- 56 sites in United States, Belgium and 15 more
- Volunteers
- 495 people
- Sponsor
- AB Science
Amyotrophic Lateral Sclerosis
Clinical Trial of Ezogabine (Retigabine) in ALS Subjects
This study evaluates the effect of retigabine (600 mg/day, 900 mg/day, or placebo) on motor neuron activity in people with Amyotrophic Lateral Sclerosis (ALS). The total study duration is approximately 14 weeks.
- Trial name
- NCT02450552
- Testing
- Ezogabine
- Where
- 12 sites in United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Brian Wainger
Amyotrophic Lateral Sclerosis
Study Evaluating TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis (ALS)
This is a global multicenter study designed to evaluate the safety and clinical effects of 4 oral doses of TCH346 (1.0, 2.5, 7.5, and 15 mg) compared to placebo in patients with mild or mild to moderate stages of ALS.
- Trial name
- NCT00072709
- Testing
- TCH346
- Where
- 9 sites in United States, Belgium and 7 more
- Volunteers
- 551 people
- Sponsor
- Novartis Pharmaceuticals
Amyotrophic Lateral Sclerosis
HEALEY ALS Platform Trial - Regimen C CNM-Au8
The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.
- Trial name
- NCT04414345
- Testing
- CNM-Au8
- Where
- United States
- Volunteers
- 161 people
- Sponsor
- Merit E. Cudkowicz, MD
Amyotrophic Lateral Sclerosis, Frontotemporal Dementia
Genetic Study of Familial and Sporadic ALS/Motor Neuron Disease, Miyoshi Myopathy and Other Neuromuscular Disorders
The investigators laboratory has been studying families with a history of ALS for more than 30 years and is continuing to use new ways to understand how genes may play a role in ALS, motor neuron disease and other neuromuscular…
- Conditions
- Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, PLS, Motor Neuron Disease
- Trial name
- NCT01459302
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Massachusetts, Worcester
Amyotrophic Lateral Sclerosis, ALS
Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS
Phase 1, open-label study of BHV-0223 in ALS.
- Conditions
- Amyotrophic Lateral Sclerosis, ALS, Lou Gehrig Disease, Lou Gehrig's Disease
- Trial name
- NCT03520517
- Testing
- BHV-0223
- Where
- 5 sites in United States
- Volunteers
- 22 people
- Sponsor
- Biohaven Pharmaceuticals, Inc.
Amyotrophic Lateral Sclerosis
A Second Intermediate-Size Expanded Access Protocol (EAP) for Pridopidine in People With Amyotrophic Lateral Sclerosis (Pridopidine EAP 2)
Protocol PL101-ALS501: This EAP will provide access to pridopidine for up to 200 patients with ALS who are ineligible for clinical trials.
- Trial name
- NCT06069934
- Testing
- Pridopidine
- Where
- 32 sites in United States, Puerto Rico
- Sponsor
- Prilenia
Amyotrophic Lateral Sclerosis
Multiple Doses of AT-1501-A201 in Adults With ALS
This is a Phase 2a, multi-center, open label, multiple dose study of AT-1501, a humanized monoclonal antibody antagonist to CD40 ligand (CD40L).
- Trial name
- NCT04322149
- Testing
- AT-1501
- Where
- 13 sites in United States, Canada
- Volunteers
- 54 people
- Sponsor
- Anelixis Therapeutics, LLC
Amyotrophic Lateral Sclerosis (ALS)
Developing New Ways to Detect Respiratory Impairment Early in ALS
The goal of this observational study is to develop new ways to detect early changes associated with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease.
- Trial name
- NCT07844590
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Thomas Jefferson University
Muscle Cramps in Amyotrophic Lateral Sclerosis
Mexiletine for the Treatment of Muscle Cramps in ALS
The purpose of this study is to determine if mexiletine is effective for the treatment of muscle cramps in Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- NCT01811355
- Testing
- Mexiletine
- Where
- 6 sites in United States
- Volunteers
- 23 people
- Sponsor
- Bjorn Oskarsson, MD
Amyotrophic Lateral Sclerosis, Lou Gehrig's Disease
Digital Speech Markers for Monitoring ALS in Spanish Speakers
The goal of this observational study is to learn how speech and breathing change over time in Spanish-speaking individuals with amyotrophic lateral sclerosis (ALS) compared to age- and gender-matched individuals without ALS.
- Conditions
- Amyotrophic Lateral Sclerosis, Lou Gehrig's Disease, ALS
- Trial name
- NCT07341334
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Nova Southeastern University
Amyotrophic Lateral Sclerosis, Lou Gehrig Disease
MRG-001 in Patients With Amyotrophic Lateral Sclerosis
The proposed study is an Open-Label, Single-Dose Study to Assess the Safety, and Pharmacodynamics (PD) signals of MRG-001 in Patients with Amyotrophic Lateral Sclerosis (ALS).
- Conditions
- Amyotrophic Lateral Sclerosis, Lou Gehrig Disease, Motor Neuron Disease, Motor Neuron Atrophy
- Trial name
- NCT06315608
- Testing
- MRG-001
- Volunteers
- 10 people
- Sponsor
- MedRegen LLC
ALS, Amyotrophic Lateral Sclerosis
Cortex Changes in Real/Imagined Movements in Amyotrophic Lateral Sclerosis (ALS)
The purpose of this study is to track areas of the brain, via functional magnetic resonance imaging (fMRI), that retain structural and functional integrity throughout the lifespan of people with amyotrophic lateral sclerosis…
- Trial name
- NCT00809224
- Where
- United States
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Amyotrophic Lateral Sclerosis, ALS
Expanded Access Protocol of BHV-0223 for Patients With Amyotrophic Lateral Sclerosis (ALS)
This is an open label expanded access protocol for the treatment of up to approximately 250 adult patients with amyotrophic lateral sclerosis (ALS) who have difficulty swallowing oral riluzole tablets and may be able to derive…
- Conditions
- Amyotrophic Lateral Sclerosis, ALS, Lou Gehrig Disease, Lou Gehrig's Disease
- Trial name
- NCT03537807
- Testing
- Riluzole
- Sponsor
- Biohaven Pharmaceuticals, Inc.
Amyotrophic Lateral Sclerosis
Safety and Efficacy Study of Creatine and Tamoxifen in Volunteers With Amyotrophic Lateral Sclerosis (ALS)
The purpose of the study is to evaluate the safety and efficacy of high dose creatine and two dosages of tamoxifen treatment in amyotrophic lateral sclerosis (ALS).
- Trial name
- SDALS-001 (NCT01257581)
- Testing
- creatine, tamoxifen
- Where
- 9 sites in United States
- Volunteers
- 60 people
- Sponsor
- Nazem Atassi
ALS (Amyotrophic Lateral Sclerosis)
Safety and Tolerability Study of CTx1000 In Participants With Amyotrophic Lateral Sclerosis
This clinical study is in participants with Amyotrophic Lateral Sclerosis and is designed to evaluate the safety and tolerability of the gene therapy CTx1000.
- Trial name
- KOANEWA (NCT07401121)
- Testing
- AAV9 Gene therapy
- Where
- Australia
- Volunteers
- 15 people
- Sponsor
- Celosia Therapeutics Pty Ltd
Amyotrophic Lateral Sclerosis (ALS)
HEALEY ALS Platform Trial - Regimen I NUZ-001
The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.
- Trial name
- NCT07410806
- Testing
- NUZ-001
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- Merit E. Cudkowicz, MD